Latest news for Tivan (OTC:TNGZF) Stock

Tivan Ltd is a critical minerals company. It is engaged in the exploration, evaluation, and development planning for its resource projects, predominantly the Speewah Vanadium Project including the development of the TIVAN+ mineral processing technology, the Sandover Project, and the Speewah Fluorite Project. The company has one reportable segment, being mineral exploration in Australia.

Tivan Ltd

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.1400</td>
<td align="right">0.390</td>
<td align="right">0.76</td>
<td>253.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">91.4468</td>
<td align="right">0.517</td>
<td align="right">0.56</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">88.5000</td>
<td align="right">0.430</td>
<td align="right">0.48</td>
<td>336</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">135.4200</td>
<td align="right">0.580</td>
<td align="right">0.43</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.6200</td>
<td align="right">0.350</td>
<td align="right">0.43</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">147.0600</td>
<td align="right">0.630</td>
<td align="right">0.43</td>
<td>2.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">235.8400</td>
<td align="right">0.970</td>
<td align="right">0.41</td>
<td>7.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">219.0300</td>
<td align="right">0.640</td>
<td align="right">0.29</td>
<td>2.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.3800</td>
<td align="right">0.200</td>
<td align="right">0.24</td>
<td>9.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.2900</td>
<td align="right">0.060</td>
<td align="right">0.14</td>
<td>933</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">103.1300</td>
<td align="right">0.110</td>
<td align="right">0.10</td>
<td>282</td>
</tr>
</tbody>
</table>
No loser in today's Pre-market session. 
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For February 24, 2025

<a href="https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm" title="https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm">https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm</a>

News

ATPC

AGAPE ATP Corp. Signs ICPO With Swiss One Oil & Gas AG For 200,000 MT Of EN590 And 2M Barrels Of Jet Fuel A1

Offerings

LFMD

LifeMD Expands Into the Behavioral Health Market. The Move Broadens LifeMD's Service Offerings To Include Teletherapy, Psychiatry And Medication Management For Common Mental Health Conditions.

Rezolve Ai&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>), the trailblazer in AI-driven commerce solutions, today unveiled a&nbsp;bold&nbsp;$1 billion Bitcoin treasury programme, kickstarting with an initial&nbsp;$100 million investment. This visionary move underscores Rezolve Ai's unwavering commitment to revolutionizing global commerce by seamlessly integrating artificial intelligence, blockchain technology, and cryptocurrency.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

RZLV

Rezolve Ai Launches $1B Bitcoin Treasury To Fuel The Future Of AI-Powered Crypto Commerce, Kickstarting With An Initial $100M Investment

This is the 13th patent granted out of a portfolio of 23 patents and covers SaverOne's innovative methodologies for limiting mobile phone use while driving
Petah Tikvah, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) -- SaverOne 2014 Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>, TASE: SVRE)), a technology company engaged in developing transportation safety solutions, is pleased to announce the award by the United States Patent and Trademark Office (USPTO) of a new patent. The patent, bearing the number 12,231,899 and issued on February 18, 2025, is entitled "System and method for managing access to software applications on a mobile communication device via a phone location unit."

SVRE

SaverOne Granted New Patent In The U.S. Entitled "System And Method For Managing Access To Software Applications On A Mobile Communication Device Via A Phone Location Unit."

Biotech

General

ARQT

Arcutis Announces Results For ZORYVE Cream In Phase 3 Trial For Pediatric Atopic Dermatitis, Meeting Primary Endpoint With 75% EASI Improvement; Itch Relief Seen In 24 Hours

The Company expects to begin 2025 with over 14,800 students, an increase of 15% over 2024.&nbsp;
While the Company anticipates overall student start growth throughout 2025, there is a planned timing shift in student starts in 2025 compared to 2024 due to a June start date shifting to July in the Company's standardized Lincoln 10.0 start calendar.&nbsp;
As a result of this start date move approximately 2,300 student starts are expected to shift from the second quarter to the third quarter. This shift is not expected to have a material impact on revenue between quarters.

Guidance

LINC

Lincoln Educational Services Expects 2025 Revenue Of $480M - $490M, Est $468.93M

Data confirms Versamune&#xAE; HPV has potential as a broadly effective treatment of HPV16-associated cancers –&nbsp;Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025
Versamune&#xAE; HPV + CRT was associated with greater and earlier clearance of blood-circulating HPV16-positive cancer cells (circulating tumor DNA/ctDNA) vs. CRT alone
100% of patients with locally advanced HPV16 cervical cancer treated with Versamune&#xAE; HPV + CRT had no detectable HPV16 ctDNA at 3-4 months vs. 50% of patients on standard-of-care CRT
Undetectable HPV ctDNA at 3-4 months was associated with improved 2-year recurrence-free survival (RFS) of 93% vs only 30% in patients with detectable HPV ctDNA
PRINCETON, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of circulating tumor DNA (ctDNA) results for its lead immunotherapy candidate, Versamune&#xAE; HPV, in <a href="https://www.globenewswire.com/Tracker?data=7s_lRXMs5dIRjelaXYS7x9fJYI8SLHGAwW4GUEwyY1g5BxFiKxjn2d9dRZXhEH2fe-mODvXI6oqtPPkA2531dRrbulwWZSAe7L0eo9gbngl5j6mE2ZwzQrE_8dnDOnIXDrwSqUIj0F0VMyIGkD4_bD_sYNTMJ_apJWsNWp4K68M6c4VUHhO0zBRYcze8qZFdhj9tAfegxFOvgFnDYyGFcgnrYmMQEj7ZXniqDbicvIr4p4MQhANI8RQ6OgSMCITO4Bx7ogR0q2mLA9BSnFyEce80sGWKkWoIdv4WwFjGmyY=">Clinical Cancer Research</a>, a journal of the American Association for Cancer Research.
The trial demonstrated that Versamune&#xAE; HPV was associated with greater and earlier clearance of HPV16-positive cancer cells from the bloodstream in patients with locally advanced cervical cancer. Notably, the elimination of HPV16-positive ctDNA correlated with extended patient survival without cancer recurrence, reinforcing its potential to improve long-term outcomes. The data underscore the potential of Versamune&#xAE; HPV in HPV16-positive cancers as the Company prepares to initiate a Phase 3 clinical trial for Versamune&#xAE; HPV in HPV16-positive head and neck squamous cell carcinoma (HNSCC) in the first quarter of this year.

PDSB

PDS Biotech Announces Circulating Tumor DNA Results For Versamune HPV In IMMUNOCERV Trial Published In Clinical Cancer Research; 100% Of Patients With Locally Advanced HPV16 Cervical Cancer Treated With Versamune HPV+ CRT Had No Detectable HPV16 ctDNA At 3-4 Months Vs. 50% Of Patients On Standard-Of-care CRT

ALLR

Allarity Therapeutics Announces New Protocol for Phase 2 Trial Of Stenoparib In Ovarian Cancer; Critical Data Expected by End of Summer 2026

JP Morgan analyst Domingos Falavina maintains Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) with a Neutral and lowers the price target from $15 to $14.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Nu Holdings, Lowers Price Target to $14

The program will demonstrate Rocket Lab's tactically responsive space capabilities using the Company's end-to-end solutions for spacecraft design, production, launch, and operations.
Rocket Lab National Security LLC, a wholly owned subsidiary of Rocket Lab USA, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, today announced the successful completion of its Critical Design Review (CDR) for the U.S. Space Force Space Systems Command's (SSC) Tactically Responsive Space (TacRS) mission, VICTUS HAZE.

Contracts

RKLB

Rocket Lab Announces The Completion Of Its Critical Design Review For The U.S. Space Force Space Systems Command's Tactically Responsive Space Mission, VICTUS HAZE

INSM

Insmed Announces FDA No Advisory Meeting For Brensocatib NDA In Non-Cystic Fibrosis Bronchiectasis

Oppenheimer analyst Leland Gershell upgrades Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) from Perform to Outperform and announces $98 price target.

Upgrades

BMRN

Oppenheimer Upgrades Biomarin Pharmaceutical to Outperform, Announces $98 Price Target

Lincoln Educational Services Expects To Make Marked Progress Toward Achieving Objectives Of $550M In Revenue And $90M In Adjusted EBITDA In 2027

Small Cap Consumer Research analyst Eric Beder reiterates Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) with a Buy and maintains $5.5 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Vera Bradley, Maintains $5.5 Price Target

<ul>
<li>Quest to provide comprehensive dialysis-related laboratory and water testing services to&nbsp;Fresenius Medical Care owned and affiliated clinics in the United States</li>
</ul>
BAD HOMBURG, Germany and SECAUCUS, N.J., Feb. 24, 2025 /PRNewswire/ --&nbsp;Fresenius Medical Care ((XETRA: FME, NYSE:<a href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading&nbsp; provider of renal-specific laboratory testing services in the U.S. &nbsp;
In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease (ESKD) and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the United States.

Quest Diagnostics Acquires Select Assets Of Fresenius's Spectra Laboratories For Dialysis Testing Services In U.S., Terms Not Disclosed

ANIX

Anixa Biosciences Announces CAR-T Therapy For Ovarian Cancer, Developed With Moffitt Cancer Center

Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) reported quarterly earnings of $0.22 per share which missed the analyst consensus estimate of $0.23 by 4.35 percent. This is unchanged from the same period last year. The company reported quarterly sales of $119.37 million which beat the analyst consensus estimate of $110.85 million by 7.69 percent. This is a 16.44 percent increase over sales of $102.52 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Lincoln Educational Servs Q4 2024 GAAP EPS $0.22 Misses $0.23 Estimate, Sales $119.37M Beat $110.85M Estimate

11 analysts have expressed a variety of opinions on T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for T. Rowe Price Group, revealing an average target of $116.73, a high estimate of $132.00, and a low estimate of $105.00. A decline of 0.31% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1740402100_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive T. Rowe Price Group is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$121.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$113.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$116.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$113.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$111.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$132.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$116.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$124.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$115.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to T. Rowe Price Group. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of T. Rowe Price Group compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for T. Rowe Price Group's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of T. Rowe Price Group's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TROW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on T. Rowe Price Group analyst ratings.</a>
<h2>Delving into T. Rowe Price Group's Background</h2>
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load US and international stock, hybrid, bond, and money market funds. At the end of October 2024, the firm had $1.607 trillion in managed assets, composed of equity (51%), balanced (34%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a US-based asset manager, deriving less than 10% of its AUM from overseas.
<h3>Financial Insights: T. Rowe Price Group</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining T. Rowe Price Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.11% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: T. Rowe Price Group's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 23.47%, the company may face hurdles in effective cost management.
Return on Equity (ROE): T. Rowe Price Group's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.16%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): T. Rowe Price Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.15%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TROW

Forecasting The Future: 11 Analyst Projections For T. Rowe Price Group

<a href="https://www.toyo-solar.com/">TOYO Co., Ltd</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOYO#NASDAQ">TOYO</a>) ("TOYO" or the "Company"), a solar solution company, is pleased to announce that its warrants are now available for trading on the OTCQB under the ticker symbol TOYWF commencing on February 24, 2025.

Comments

Tivan

News

Latest news for Tivan (OTC:TNGZF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga